HIV research focus on finding a cure

Related tags: HIV

With 34 million people around the world living with HIV/AIDS, preventing and treating HIV infection remains an enormous global challenge. At GSK, we have a long commitment to HIV treatment, from the development of the world’s first breakthrough HIV medicine in the 1980s, to our leadership today through ViiV Healthcare, our dedicated HIV company.

This has recently launched new medicines that enhance treatment for patients. We also currently have clinical trials underway testing innovative long-acting medicines that could treat and prevent HIV infections. In 2015 we established a research centre with the University of North Carolina at Chapel Hill (UNC-Chapel Hill) entirely focused on researching a cure to eventually eradicate HIV.

  • 35 million

    people have died of AIDS related causes since 1984.

  • 4,600

    people still die every day due to AIDS related causes.

  • 2.5 million

    people were newly infected with HIV in 2011.

Both GSK and UNC-Chapel Hill have a long history of helping people with HIV/AIDS. In fact, UNC-Chapel Hill admitted its first HIV patient in 1981 at the beginning of the AIDS epidemic and has conducted decades of research and clinical trials. We were the company to develop the world’s first breakthrough treatment for HIV/AIDS—AZT. By combining our resources, research teams, and expertise, we hope to be able to make a meaningful impact toward finding a cure.